DeepMed Research

mipetresgene autoleucel

Generic Name: mipetresgene autoleucel

Clinical Trials

Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma

Phase 1

Completed

Conditions: Synovial Sarcoma

Interventions: Biological: TBI-1301
Drug: Cyclophosphamide

First Posted Date: 2017-08-15

Last Posted Date: 2024-11-20

Lead Sponsor: Takara Bio Inc.

Target Recruit Count: 8

Registration Number: NCT03250325

Locations: 🇯🇵
National Hospital Organization Osaka National Hospital, Osaka, Japan
🇯🇵
Mie University Hospital, Tsu, Mie, Japan
🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

and more 2 locations

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Phase 1

Active, not recruiting

Conditions: NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients
Esophageal Cancer
Ovarian Cancer
Synovial Sarcoma
Melanoma
Lung Cancer
Bladder Cancer
Liver Cancer

Interventions: Drug: Cyclophosphamide
Biological: TBI-1301
Drug: Fludarabine

First Posted Date: 2016-08-16

Last Posted Date: 2024-10-10

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 22

Registration Number: NCT02869217

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Investigator Initiated Phase 1 Study of TBI-1301

Phase 1

Conditions: Solid Tumors

Interventions: Drug: TBI-1301
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2015-02-19

Last Posted Date: 2018-10-24

Lead Sponsor: Mie University

Target Recruit Count: 9

Registration Number: NCT02366546

Locations: 🇯🇵
Mie University Hospital, Tsu, Mie, Japan

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy